Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
On November 16, 2026, 20/20 Biolabs, Inc. (the “Company”)
issued a press release regarding its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished
as Exhibit 99.1 to this report.
The information furnished with this Item 2.02, including
Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under
Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except as expressly set forth by specific reference
in such a filing.
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Exhibit 99.1
20/20 BioLabs Reports Third Quarter 2026 Financial
Results and Recent Business Updates
OneTest™ Revenue Increased 4.1% to $1.36
Million for First Nine Months of 2026, with Gross Margin Expanding to 32.8%
Vermont Executes Two-Year Firefighter Cancer
Screening Contract with Testing Expected to Contribute Revenue in Q4
New Laboratory Franchise Model and 2027 Licensing
Plans Aim to Broaden OneTest™ Distribution
Cash of $3.63 Million and No Outstanding Debt
as of September 30, 2026
GAITHERSBURG, MD — November 16, 2026
— 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in
AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today reported its financial
and operational results for the third quarter ended September 30, 2026.
Third Quarter and Recent Operational Highlights
| ● | OneTest™ revenue increased 4.1% to $1.36
million for the first nine months of 2026, representing 92.8% of total revenue. |
| ● | OneTest™ gross profit increased 15.6% to
$0.45 million for the first nine months of 2026, with gross margin expanding to 32.8% from 29.5%. |
| ● | Third quarter revenue was $0.38 million, compared
to $0.42 million in the prior year period, reflecting the timing of firefighter cancer screening programs. |
| ● | Vermont executed a two-year contract specifying
OneTest™ Premium for its statewide cancer screening program covering approximately 4,500 firefighters. Testing is expected to begin
contributing to revenue in Q4 2026. |
| ● | Continued OneTest™ testing through Maryland's
state-funded firefighter cancer screening program, with 18 groups of fire departments awarded more than $520,000 in grants. |
| ● | Introduced a OneTest™ laboratory franchise
model to expand distribution through regional laboratories under a royalty-based structure. |
| ● | Announced plans to begin licensing its patented
protein tumor marker testing technology to laboratories in the U.S. and internationally in 2027. |
| ● | Entered into $1.30 million of non-cancelable
customer contracts during the first nine months of 2026. |
| ● | Cash and cash equivalents totaled $3.63 million
as of September 30, 2026, with no outstanding borrowings. |
Management Commentary
President and Chief Executive Officer Jonathan
Cohen commented, “OneTest™ revenue grew 4.1% through the first nine months of the year, with gross profit increasing 15.6%.
While third quarter revenue was below the prior year, much of this reflected the timing of our state-funded firefighter cancer screening
programs. Maryland completed a significant portion of its testing in the second quarter, while the start of Vermont’s program shifted
into the fourth quarter. Vermont has now executed its two-year contract, and we expect testing to begin contributing to revenue before
year-end.”
“We are also working on new ways to reach
more customers. Our franchise model would allow established regional laboratories to offer OneTest™ in their markets, without requiring
us to build a national sales force. We have received preliminary interest from laboratories in the United States and plan to begin licensing
our protein tumor marker approach to clinical laboratories in 2027.”
“With more than 25,000 firefighters screened
to date, we are continuing to build the real-world evidence to support our regulatory strategy. We believe recent developments in the
MCED testing industry are encouraging, and we remain focused on our goal of obtaining FDA authorization and Medicare reimbursement for
OneTest™ for Cancer by the end of 2028,” concluded Cohen.
Chief Financial Officer Alan Bergman added, “We
ended the third quarter with $3.63 million in cash and no outstanding borrowings, compared to $1.03 million in cash at year-end 2025.
Our net loss narrowed to $1.38 million from $1.51 million in the second quarter, while operating expenses declined 4.0% sequentially.”
“Gross margin was lower this quarter due
to reduced testing volume, but our laboratory has the capacity to support additional testing without a corresponding increase in certain
operating costs. As testing under the Vermont contract and other programs increases, we expect to benefit from better utilization of our
existing laboratory capacity while continuing to manage expenses,” concluded Bergman.
Third Quarter 2026 Financial Results
Total revenue for the three months ended September
30, 2026 was $0.38 million, compared to $0.42 million in the prior year period. OneTest™ revenue was $0.35 million, compared to
$0.36 million, and represented 92.8% of total revenue, up from 86.3%. The decrease primarily reflected the timing of state-funded firefighter
cancer screening programs.
Total cost of revenue was $0.28 million, compared
to $0.27 million in the prior year period.
Gross profit was $0.10 million, compared to $0.15
million in the prior year period. Gross margin was 25.5%, compared to 34.7%, reflecting lower testing volume and the impact of fixed laboratory
costs.
Operating expenses were $1.49 million, compared
to $0.95 million in the prior year period and $1.55 million in Q2 2026. The year-over-year increase primarily reflected higher public
company expenses.
Total other income, net, was $0.01 million, compared
to other expense, net, of $0.03 million in the prior year period. The Company recorded no interest expense during the quarter.
Net loss was $1.38 million, compared to $0.83
million in the prior year period and $1.51 million in Q2 2026. Net loss included approximately $0.3 million in non-cash charges.
Cash and cash equivalents totaled $3.63 million
as of September 30, 2026, compared to $1.03 million at year-end 2025, primarily reflecting $6.0 million in Series E preferred financing
completed during the first half of 2026. The Company had no outstanding borrowings at quarter end.
First Nine Months 2026 Financial Results
Total revenue for the nine months ended September
30, 2026 was $1.46 million, compared to $1.51 million in the prior year period. OneTest™ revenue increased 4.1% to $1.36 million
from $1.31 million, primarily driven by Maryland firefighter cancer screening programs.
Gross profit was $0.46 million, compared to $0.47
million in the prior year period. Gross margin was 31.7%, compared to 31.5%. OneTest™ gross profit increased 15.6% to $0.45 million,
with gross margin expanding to 32.8% from 29.5%.
Total operating expenses were $4.54 million, compared
to $2.89 million in the prior year period, primarily reflecting costs associated with the Company's transition to a Nasdaq-listed public
company.
Net loss was $5.06 million, compared to $2.43
million in the prior year period. Net loss included approximately $2.0 million in non-cash charges and $0.98 million in other expense,
net, primarily related to convertible notes converted or exchanged during the first half of 2026.
About 20/20 BioLabs
20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and
commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The Company
offers two families of lab tests under the OneTest brand. OneTest™ for Cancer is a multi-cancer early detection blood test and OneTest™
for Longevity measures inflammatory biomarkers and is commercially available. OneTest’s tests are designed to be affordable and
accessible and can be conveniently utilized at home using new, upper-arm capillary collection devices as an alternative to traditional
venipuncture. Tests are run in the Company’s College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement
Amendments (CLIA) licensed laboratory in Gaithersburg, Maryland.
For more information visit https://2020biolabs.com.
Forward-Looking Statements
This press release contains forward-looking statements
that are based on our management’s beliefs and assumptions and on information currently available to us. All statements other than
statements of historical facts are forward-looking statements. These statements relate to future events or to our future financial performance
and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance
or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied
by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about our goals and strategies;
our future business development, financial condition and results of operations; expected changes in our revenue, costs or expenditures;
growth of and competition trends in our industry; our expectations regarding demand for, and market acceptance of, our products; our expectations
regarding our relationships with investors, institutional funding partners and other parties we collaborate with; fluctuations in general
economic and business conditions in the market in which we operate; and relevant government policies and regulations relating to our industry.
In some cases, you can identify forward-looking
statements by terms such as “may,” “could,” “will,” “should,” “would,” “expect,”
“plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,”
“potential,” “project” or “continue” or the negative of these terms or other comparable terminology.
These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and
unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results.
Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Item
1A “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities
and Exchange Commission, or the SEC, on March 31, 2026 and elsewhere in our filings with the SEC. If one or more of these risks or uncertainties
occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected
by the forward-looking statements. No forward-looking statement is a guarantee of future performance.
In addition, statements that “we believe”
and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available
to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information
may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or
review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to
unduly rely upon these statements.
The forward-looking statements made in this press
release relate only to events or information as of the date on which the statements are made in this press release. Except as expressly
required by the federal securities laws, there is no undertaking to publicly update or revise any forward-looking statements, whether
as a result of new information, future events, changed circumstances or any other reason.
Investor Relations
Chris Tyson
MZ Group
Direct: 949-491-8235
AIDX@mzgroup.us
20/20 BIOLABS, INC.
CONDENSED BALANCE SHEETS
(UNAUDITED)
| | |
September 30, 2026 | | |
December 31, 2025 | |
| Assets | |
| | |
| |
| Current assets: | |
| | |
| |
| Cash and cash equivalents | |
$ | 3,633,711 | | |
$ | 1,025,987 | |
| Accounts receivable, net | |
| 173,985 | | |
| 199,954 | |
| Inventory | |
| 102,568 | | |
| 116,217 | |
| Prepaid expenses and other current assets | |
| 119,525 | | |
| 128,975 | |
| Total current assets | |
| 4,029,789 | | |
| 1,471,133 | |
| License agreement, net | |
| 259,893 | | |
| 271,143 | |
| Property and equipment, net | |
| 24,525 | | |
| 56,677 | |
| Intangible asset, net | |
| 205,168 | | |
| 202,264 | |
| Right-of-use assets, net | |
| 475,670 | | |
| 605,289 | |
| Deferred financing costs | |
| - | | |
| 1,507,794 | |
| Other assets | |
| 23,057 | | |
| 23,057 | |
| Total assets | |
$ | 5,018,102 | | |
$ | 4,137,357 | |
| | |
| | | |
| | |
| Liabilities and Stockholders’ Equity (Deficit) | |
| | | |
| | |
| Current liabilities: | |
| | | |
| | |
| Accounts payable | |
$ | 1,045,819 | | |
$ | 868,545 | |
| Accrued liabilities | |
| 642,335 | | |
| 785,784 | |
| Accrued dividends – Series E convertible preferred stock | |
| 128,441 | | |
| - | |
| Deferred revenue – current | |
| 478,937 | | |
| 414,871 | |
| Derivative liability – current | |
| - | | |
| 143,382 | |
| Convertible notes payable – current | |
| - | | |
| 74,611 | |
| Operating lease liability – current | |
| 195,848 | | |
| 175,948 | |
| Total current liabilities | |
| 2,491,380 | | |
| 2,463,141 | |
| | |
| | | |
| | |
| Long-term liabilities: | |
| | | |
| | |
| Convertible notes payable, net | |
| - | | |
| 619,355 | |
| Deferred revenue – long-term | |
| 29,372 | | |
| 41,816 | |
| Derivative liabilities – long-term | |
| - | | |
| 543,545 | |
| Operating lease liability – long term | |
| 329,847 | | |
| 488,725 | |
| Total long-term liabilities | |
| 359,219 | | |
| 1,693,441 | |
| | |
| | | |
| | |
| Total liabilities | |
| 2,850,599 | | |
| 4,156,582 | |
| | |
| | | |
| | |
| Commitments and contingencies (Note 9) | |
| - | | |
| - | |
| | |
| | | |
| | |
| Contingently redeemable convertible preferred stock: | |
| | | |
| | |
| Series E convertible preferred stock, $0.01 par value; 45,000 authorized; 5,015 and 0 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively; liquidation preference of $5,639,555 | |
| 1,556,307 | | |
| - | |
| | |
| | | |
| | |
| Stockholders’ equity (deficit): | |
| | | |
| | |
| Series D preferred stock, $0.01 par value; 936,329 authorized; 0 and 101,565 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | |
| - | | |
| 1,016 | |
| Series C preferred stock, $0.01 par value; 3,340,909 authorized; 0 and 1,204,040 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | |
| - | | |
| 12,040 | |
| Series B preferred stock, $0.01 par value; 3,569,405 authorized; 0 and 1,471,487 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | |
| - | | |
| 14,715 | |
| Series A-2 preferred stock, $0.01 par value; 800,000 authorized; 0 and 442,402 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | |
| - | | |
| 4,424 | |
| Series A-1 preferred stock, $0.01 par value; 978,000 authorized; 0 and 651,465 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | |
| - | | |
| 6,515 | |
| Series A preferred stock, $0.01 par value; 1,303,000 authorized; 0 and 846,368 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | |
| - | | |
| 8,464 | |
| Common stock, $0.01 par value; 500,000,000 and 50,000,000 authorized; 13,367,204 and 5,442,249 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | |
| 133,672 | | |
| 54,422 | |
| Additional paid-in capital | |
| 38,781,013 | | |
| 33,126,398 | |
| Accumulated deficit | |
| (38,303,489 | ) | |
| (33,247,219 | ) |
| Total stockholders’ equity (deficit) | |
| 611,196 | | |
| (19,225 | ) |
| Total liabilities, contingently redeemable preferred stock and stockholders’ equity (deficit) | |
$ | 5,018,102 | | |
$ | 4,137,357 | |
20/20 BIOLABS, INC.
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)
| | |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Revenues | |
$ | 380,216 | | |
$ | 417,979 | | |
$ | 1,464,162 | | |
$ | 1,506,859 | |
| Cost of revenues | |
| 283,343 | | |
| 272,913 | | |
| 999,678 | | |
| 1,032,735 | |
| Gross profit | |
| 96,873 | | |
| 145,066 | | |
| 464,484 | | |
| 474,124 | |
| | |
| | | |
| | | |
| | | |
| | |
| Operating expenses: | |
| | | |
| | | |
| | | |
| | |
| Sales, general and administrative | |
| 1,363,385 | | |
| 814,179 | | |
| 4,007,461 | | |
| 2,430,134 | |
| Research and development | |
| 123,385 | | |
| 131,060 | | |
| 534,499 | | |
| 462,015 | |
| Total operating expenses | |
| 1,486,770 | | |
| 945,239 | | |
| 4,541,960 | | |
| 2,892,149 | |
| | |
| | | |
| | | |
| | | |
| | |
| Operating loss | |
| (1,389,897 | ) | |
| (800,173 | ) | |
| (4,077,476 | ) | |
| (2,418,025 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Other (expense) income: | |
| | | |
| | | |
| | | |
| | |
| Interest expense | |
| - | | |
| (29,547 | ) | |
| (539,253 | ) | |
| (31,222 | ) |
| Interest income | |
| 14,806 | | |
| 4,181 | | |
| 35,935 | | |
| 18,312 | |
| Loss on change in fair value of warrant liability | |
| - | | |
| - | | |
| (148,766 | ) | |
| - | |
| Loss on issuance of convertible note | |
| - | | |
| - | | |
| (326,595 | ) | |
| - | |
| Other expense, net | |
| - | | |
| - | | |
| (115 | ) | |
| (115 | ) |
| Total other (expense) income | |
| 14,806 | | |
| (25,366 | ) | |
| (978,794 | ) | |
| (13,025 | ) |
| Provision for income taxes | |
| - | | |
| - | | |
| - | | |
| - | |
| Net loss | |
| (1,375,091 | ) | |
| (825,539 | ) | |
| (5,056,270 | ) | |
| (2,431,050 | ) |
| Deemed dividend on warrant modifications | |
| - | | |
| - | | |
| (1,124,676 | ) | |
| - | |
| Preferred stock dividends | |
| (128,441 | ) | |
| - | | |
| (304,295 | ) | |
| - | |
| Net loss attributable to common stockholders | |
$ | (1,503,532 | ) | |
$ | (825,539 | ) | |
$ | (6,485,241 | ) | |
$ | (2,431,050 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Basic and diluted net loss per common share | |
$ | (0.12 | ) | |
$ | (0.17 | ) | |
$ | (0.62 | ) | |
$ | (0.50 | ) |
| Weighted-average common shares outstanding, basic and diluted | |
| 12,958,114 | | |
| 4,849,770 | | |
| 10,484,242 | | |
| 4,849,770 | |
20/20 BIOLABS, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
| | |
Nine Months Ended September 30, | |
| | |
2026 | | |
2025 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | |
| | |
| |
| Net loss | |
$ | (5,056,270 | ) | |
$ | (2,431,050 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
| Depreciation and amortization | |
| 34,601 | | |
| 48,743 | |
| Stock based compensation | |
| 710,137 | | |
| 388,950 | |
| Amortization of license fees | |
| 18,750 | | |
| 16,875 | |
| Issuance of common stock for services | |
| 283,595 | | |
| - | |
| Loss on issuance of convertible note | |
| 326,595 | | |
| - | |
| Amortization of right-of-use assets, net of liabilities | |
| (9,359 | ) | |
| (5,516 | ) |
| Amortization of debt discount | |
| 515,583 | | |
| 17,238 | |
| Change in fair value of derivative liability | |
| 148,766 | | |
| - | |
| Changes in operating assets and liabilities: | |
| | | |
| | |
| Accounts receivable | |
| 25,969 | | |
| (1,601 | ) |
| Inventory | |
| 13,649 | | |
| (7,598 | ) |
| Prepaid expenses and other assets | |
| 9,450 | | |
| (22,605 | ) |
| Accounts payable | |
| 254,847 | | |
| 256,081 | |
| Accrued liabilities | |
| (134,784 | ) | |
| 250,109 | |
| Settlement liability | |
| - | | |
| 80,000 | |
| Interest payable | |
| - | | |
| 13,984 | |
| Deferred revenue | |
| 51,622 | | |
| (11,663 | ) |
| Net cash used in operating activities | |
| (2,806,849 | ) | |
| (1,408,053 | ) |
| | |
| | | |
| | |
| CASH FLOWS FROM INVESTING ACTIVITIES: | |
| | | |
| | |
| Purchases of intangible assets, including patents | |
| (5,354 | ) | |
| - | |
| License agreement | |
| (7,500 | ) | |
| - | |
| Net cash used in investing activities | |
| (12,854 | ) | |
| - | |
| | |
| | | |
| | |
| CASH FLOWS FROM FINANCING ACTIVITIES: | |
| | | |
| | |
| Proceeds from issuance of convertible notes payable | |
| 250,000 | | |
| 576,561 | |
| Proceeds from issuance of series D preferred stock | |
| - | | |
| 192,338 | |
| Proceeds from issuance of series E convertible preferred stock | |
| 6,000,000 | | |
| - | |
| Offering costs | |
| (822,573 | ) | |
| - | |
| Net cash provided by financing activities | |
| 5,427,427 | | |
| 768,899 | |
| | |
| | | |
| | |
| Increase (decrease) in cash and cash equivalents | |
| 2,607,724 | | |
| (639,154 | ) |
| Cash and cash equivalents, beginning of period | |
| 1,025,987 | | |
| 1,784,009 | |
| Cash and cash equivalents, end of period | |
$ | 3,633,711 | | |
$ | 1,144,855 | |
| | |
| | | |
| | |
| Supplemental disclosures of cash flow information: | |
| | | |
| | |
| Cash paid for interest | |
$ | - | | |
$ | - | |
| Cash paid for income taxes | |
$ | - | | |
$ | - | |
| | |
| | | |
| | |
| Non-cash disclosures of cash flow information: | |
| | | |
| | |
| Conversion of preferred stock to common stock | |
$ | 393,154 | | |
$ | - | |
| Deferred offering costs – issuance of common stock and warrants as offering costs | |
$ | 3,654,057 | | |
$ | 452,736 | |
| Accrued dividends on series E convertible preferred stock | |
$ | 128,441 | | |
$ | - | |
| Relief of accounts payable through the issuance of common stock | |
$ | 77,574 | | |
$ | - | |
| Deemed dividend on warrant modifications | |
$ | 1,124,676 | | |
$ | - | |
| Issuance of preferred stock for dividends on series E convertible preferred stock | |
$ | 175,854 | | |
$ | - | |
| Derivative liabilities recognized as debt discounts | |
$ | 541,199 | | |
$ | 152,384 | |
| Derivative liabilities reclassified to equity | |
$ | 1,381,124 | | |
$ | - | |
| Conversion of convertible notes payable and accrued interest to common stock | |
$ | 834,812 | | |
$ | - | |
| Conversion of convertible notes payable and accrued interest to series E convertible preferred stock | |
$ | 583,197 | | |
$ | - | |